Etoposide

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

• Acute Lymphoblastic Leukaemias (ALL)
• Acute Myeloid Leukemia
• Advanced Hodgkin's Lymphoma
• Ewing's Sarcoma
• Gestational Trophoblastic Neoplasia
• Merkel cell cancer
• Multiple Myeloma (MM)
• Neuroblastoma (NB)
• Neuroendocrine Tumors
• Non-Hodgkin's Lymphomas
• Non-Small Cell Lung Cancer (NSCLC)
• Osteosarcoma
• Ovarian Cancer
• Prostate Cancer
• Retinoblastoma
• Small Cell Lung Cancer (SCLC)
• Wilms' tumor
• Locally advanced Thymoma
• Metastatic Thymic Cancer
• Refractory Sarcoma
• Refractory Testicular cancer